跳转至内容
Merck
CN

Haloperidol for treatment of cannabinoid hyperemesis syndrome.

The American journal of emergency medicine (2013-04-16)
Jami L Hickey, Joanne C Witsil, Mark B Mycyk
摘要

Cannabinoid hyperemesis syndrome (CHS) is a condition characterized by cyclical vomiting without other identifiable cause in patients with chronic cannabis use. Patients with CHS report that compulsive bathing and hot showers are the only reliable treatments to improve symptoms. Cannabinoid hyperemesis syndrome is usually unresponsive to conventional pharmacologic antiemetics, and patients often require hospital admission. We report a case of CHS that improved significantly after treatment with haloperidol in the emergency department.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氟哌啶醇, powder
Supelco
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
氟哌啶醇, European Pharmacopoeia (EP) Reference Standard